Cargando…

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is a highly aggressive disease with a poor prognosis. Although most patients initially respond to topoisomerase inhibitors, resistance rapidly emerges. The aim, therefore, is to overcome resistance to topoisomerase I (irinotecan) or II (etoposide) inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omori, Miwako, Noro, Rintaro, Seike, Masahiro, Matsuda, Kuniko, Hirao, Mariko, Fukuizumi, Aya, Takano, Natsuki, Miyanaga, Akihiko, Gemma, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346178/ https://www.ncbi.nlm.nih.gov/pubmed/35719112 http://dx.doi.org/10.1111/1759-7714.14527

Ejemplares similares

CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis
por: Fukuizumi, Aya, et al.
Publicado: (2021)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
por: Hisakane, Kakeru, et al.
Publicado: (2021)

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
por: Takahashi, Satoshi, et al.
Publicado: (2021)

Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
por: Fukuizumi, Aya, et al.
Publicado: (2015)

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
por: Sugano, Teppei, et al.
Publicado: (2020)

The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non‐small cell lung cancer
por: Shimizu, Masamitsu, et al.
Publicado: (2022)

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
por: Matsumoto, Masaru, et al.
Publicado: (2015)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
por: Terashima, Yuto, et al.
Publicado: (2023)

Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report
por: Hayashi, Anna, et al.
Publicado: (2022)

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
por: NISHIJIMA, NOBUHIKO, et al.
Publicado: (2016)

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
por: Tozuka, Takehiro, et al.
Publicado: (2023)

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
por: Nakamichi, Shinji, et al.
Publicado: (2018)

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice
por: Gardner, Erin R, et al.
Publicado: (2009)

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
por: Iso, Hirokazu, et al.
Publicado: (2023)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato, Yuki, et al.
Publicado: (2021)

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
por: Eadie, Laura N., et al.
Publicado: (2018)

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006)

Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B
por: Noro, Rintaro, et al.
Publicado: (2020)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
por: Nishima, Shunichi, et al.
Publicado: (2020)

Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
por: Gemma, Akihiko, et al.
Publicado: (2006)

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
por: Misawa, Kazuhito, et al.
Publicado: (2023)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat
por: Wu, Chung-Pu, et al.
Publicado: (2021)

ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro
por: Moriyama, Gaku, et al.
Publicado: (2018)

GENETIC POLYMORPHISMS OF THE ADENOSINE TRIPHOSPHATE-BINDING CASSETTE TRANSPORTERS(ABCG2, ABCB1) AND GEFITINIB TOXICITY
por: TAMURA, MARIKO, et al.
Publicado: (2012)

Children’s motivation overcame parental hesitation: active school transportation in Sweden
por: Rutberg, Stina, et al.
Publicado: (2019)

ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells
por: Liu, Changfu, et al.
Publicado: (2021)

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Mobility Repertoires: How Chinese Overseas Students Overcame Pandemic-Induced Immobility
por: Liu, Jiaqi M., et al.
Publicado: (2023)

ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure
por: El Biali, Myriam, et al.
Publicado: (2021)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Down-regulation of ABCG2 and ABCB4 transporters in the placenta of rats exposed to cadmium
por: Liu, Lili, et al.
Publicado: (2016)

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2()
por: de Gooijer, Mark C., et al.
Publicado: (2018)

The Robot-Assisted Extravesical Anti-reflux Surgery: How We Overcame the Learning Curve
por: Sahadev, Ravindra, et al.
Publicado: (2019)

Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma
por: IIJIMA, YOSHIHITO, et al.
Publicado: (2014)

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mt96pjdu8a8nq6pnu2ru70iamp